Choice of Valve Substitute in the Era of Oral Anticoagulation Self-Management

NCT01269905 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2011-01-04

No results posted yet for this study

Summary

The optimal valve substitute for patients between 60-70 years is controversial. We compared anticoagulation-related adverse events (ARAE) in patients receiving mechanical heart valve replacement (MHVR) on INR self-management vs. stentless bioprosthesis, to assess whether the risk of structural valve deterioration (SVD) is still out-weighted by the benefit of not requiring permanent anticoagulation.

Conditions

  • Anticoagulation
  • Mechanical Heart Valve Replacement

Sponsors & Collaborators

  • Johann Wolfgang Goethe University Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01269905 on ClinicalTrials.gov